BRCA1 and BRCA2 pathogenic variant (PV) prevalences in females diagnosed with breast cancer (BC) have been estimated as 1.1% and 1.5%, respectively.1 Survivors of BC found to carry BRCA1 and BRCA2 PVs are likely to increase in number because of the increasing frequency of genetic testing in oncology2 and good survival outcomes, with 15-year BC-specific survival rates estimated as around 81% in BRCA1 and 75% in BRCA2 PV carriers.3 Second primary cancer (SPC) risks for BRCA1 and BRCA2 PV carriers remain uncertain. This evidence concerns the gene BRCA1 and breast cancer.